Clinical Lipid Specialist (CLS) Certification Exam — Questions and Answers

Question 1: Which statement about the relationship between dietary carbohydrate quality and lipid levels is most accurate?

High-fiber carbohydrates raise triglycerides similarly to simple sugars
All carbohydrates equally raise triglycerides regardless of glycemic index
Carbohydrate intake has no meaningful effect on HDL-C levels
Replacing refined carbohydrates with high-fiber, low-glycemic options reduces triglycerides and improves HDL (Correct answer)

Correct answer: Replacing refined carbohydrates with high-fiber, low-glycemic options reduces triglycerides and improves HDL

Replacing refined, high-glycemic carbohydrates with fiber-rich low-glycemic alternatives reduces postprandial lipemia, lowers VLDL production, and modestly raises HDL-C.

Question 2: Which clinical finding distinguishes xanthelasma from tendon xanthomas in FH patients?

Xanthelasma are soft yellowish plaques on eyelid skin; tendon xanthomas are firm nodules within tendon tissue (Correct answer)
Xanthelasma occur only in homozygous FH; tendon xanthomas in heterozygous FH
Xanthelasma contain triglycerides; tendon xanthomas contain cholesterol esters
Xanthelasma are found on tendons; tendon xanthomas on eyelids

Correct answer: Xanthelasma are soft yellowish plaques on eyelid skin; tendon xanthomas are firm nodules within tendon tissue

Xanthelasma are soft lipid deposits on periorbital skin with lower FH specificity, while tendon xanthomas are firm cholesterol deposits within tendon fibers highly specific for FH.

Question 3: Sitosterolemia (phytosterolemia) results from mutations in which transporters?

ABCA1 and ABCG1
NPC1L1 and ABCG5
LDL receptor and PCSK9
ABCG5 and ABCG8 (Correct answer)

Correct answer: ABCG5 and ABCG8

Loss-of-function mutations in ABCG5 or ABCG8 impair the secretion of plant sterols back into the intestinal lumen and bile, causing accumulation of sitosterol and other plant sterols in blood and tissues.

Question 4: Lomitapide is approved for homozygous FH and works by inhibiting which protein?

ATP citrate lyase
NPC1L1
PCSK9
Microsomal triglyceride transfer protein (MTP) (Correct answer)

Correct answer: Microsomal triglyceride transfer protein (MTP)

Lomitapide inhibits MTP, which is essential for assembling VLDL and chylomicrons, thereby reducing hepatic and intestinal lipoprotein secretion.

Question 5: A direct (beta-quantification) LDL-C measurement differs from the Friedewald-calculated LDL-C primarily in which clinical scenario?

When HDL-C is above 60 mg/dL
When triglycerides are below 100 mg/dL
When total cholesterol is above 300 mg/dL
When triglycerides exceed 400 mg/dL or in type III hyperlipoproteinemia (Correct answer)

Correct answer: When triglycerides exceed 400 mg/dL or in type III hyperlipoproteinemia

Direct LDL-C measurement by ultracentrifugation or homogeneous assay is essential when TG exceed 400 mg/dL or when type III dyslipidemia is present, conditions that invalidate the Friedewald equation.

Question 6: How does lipid panel interpretation contribute to professional excellence in CLS certification?

It has no measurable impact on practice
It benefits organizations but not individual practitioners
It enhances competency, improves outcomes, and supports continuous professional growth (Correct answer)
It only matters during certification exams

Correct answer: It enhances competency, improves outcomes, and supports continuous professional growth

Lipid Panel Interpretation is integral to CLS professional excellence, directly enhancing competency and driving measurable improvement in practice outcomes.

Question 7: What is the relationship between secondary causes of dyslipidemia and overall Clinical Lipid Specialist Certification professional competency?

They are completely unrelated areas
It is an essential component that strengthens the overall competency framework (Correct answer)
It only applies to senior practitioners
It is a minor supplementary skill

Correct answer: It is an essential component that strengthens the overall competency framework

Secondary Causes of Dyslipidemia is an essential component of the CLS competency framework, strengthening overall professional capability and credibility.

Question 8: What tool estimates 10-year risk for heart disease?

CHA2DS2-VASc
CAGE questionnaire
ASCVD Risk Calculator (Correct answer)
Framingham score

Correct answer: ASCVD Risk Calculator

The ASCVD (Atherosclerotic Cardiovascular Disease) Risk Calculator is a widely used tool that estimates an individual's 10-year risk of developing a first ASCVD event, such as a heart attack or stroke. It incorporates various factors like age, sex, race, cholesterol levels, blood pressure, diabetes status, and smoking history to provide a personalized risk assessment. This helps guide treatment decisions for primary prevention.

Question 9: Which lipid is considered 'good cholesterol'?

LDL
Triglycerides
HDL (Correct answer)
Phospholipids

Correct answer: HDL

HDL (High-Density Lipoprotein) is considered 'good cholesterol' because it helps remove excess cholesterol from the body's tissues and transport it back to the liver for excretion or reprocessing. This process, known as reverse cholesterol transport, helps prevent the buildup of plaque in arteries. In contrast, LDL is often called 'bad cholesterol'.

Question 10: What challenge is most commonly encountered in familial hypercholesterolemia management within Clinical Lipid Specialist Certification practice?

Unlimited budget allocation
Resistance to change and difficulty maintaining consistency across stakeholders (Correct answer)
Lack of available training materials
Excessive regulatory support

Correct answer: Resistance to change and difficulty maintaining consistency across stakeholders

The most common challenge in familial hypercholesterolemia management is overcoming resistance to change while maintaining consistent implementation across diverse stakeholders.

Question 11: What is the cornerstone of lifestyle modification for dyslipidemia?

Dietary fat reduction (Correct answer)
Increasing sugar intake
Taking aspirin
Vitamin supplements

Correct answer: Dietary fat reduction

Dietary fat reduction, particularly of saturated and trans fats, is a cornerstone of lifestyle modification for dyslipidemia. Limiting these unhealthy fats helps lower LDL cholesterol and improve overall lipid profiles. This, combined with increased fiber and plant-based foods, is crucial for cardiovascular health and managing lipid levels.

Question 12: In a patient with familial hypercholesterolemia (FH) and LDL-C of 210 mg/dL despite maximum statin plus ezetimibe, which is the most appropriate next step?

Add a PCSK9 inhibitor (evolocumab or alirocumab) (Correct answer)
Switch to a lower statin dose to reduce side effects
Initiate LDL apheresis without further medication changes
Add niacin 1,500 mg daily

Correct answer: Add a PCSK9 inhibitor (evolocumab or alirocumab)

PCSK9 inhibitors are indicated for FH patients who do not achieve adequate LDL-C reduction on maximum statin plus ezetimibe therapy.

Question 13: Plant sterols and stanols lower LDL cholesterol primarily through which mechanism?

Activating LDL receptors on hepatocytes
Increasing fecal bile acid excretion via viscosity
Competing with dietary and biliary cholesterol for intestinal absorption (Correct answer)
Inhibiting HMG-CoA reductase in the liver

Correct answer: Competing with dietary and biliary cholesterol for intestinal absorption

Plant sterols and stanols are structural analogs of cholesterol that displace cholesterol from intestinal micelles, reducing its absorption by 30-50%.

Question 14: Which enzyme is responsible for breaking down triglycerides?

Trypsin
Pepsin
Amylase
Lipase (Correct answer)

Correct answer: Lipase

Lipase is the specific enzyme responsible for breaking down triglycerides, which are a type of fat. It catalyzes the hydrolysis of triglycerides into fatty acids and glycerol, making them available for absorption and energy use. Other enzymes like amylase, pepsin, and trypsin break down carbohydrates and proteins, respectively.

Question 15: A patient with metabolic syndrome shows TG 200 mg/dL, HDL 38 mg/dL, and small dense LDL particles. This pattern is referred to as:

Polygenic hypercholesterolemia
Isolated hypertriglyceridemia
Familial combined hyperlipidemia
Atherogenic dyslipidemia triad (Correct answer)

Correct answer: Atherogenic dyslipidemia triad

The atherogenic dyslipidemia triad—elevated TG, low HDL, and small dense LDL—is a hallmark of insulin resistance and metabolic syndrome.

Question 16: A lipid panel shows TC 180 mg/dL, HDL-C 55 mg/dL, TG 90 mg/dL, and LDL-C 107 mg/dL. What is the calculated non-HDL cholesterol?

107 mg/dL
90 mg/dL
125 mg/dL (Correct answer)
143 mg/dL

Correct answer: 125 mg/dL

Non-HDL cholesterol = Total cholesterol − HDL-C = 180 − 55 = 125 mg/dL, encompassing all atherogenic lipoproteins including LDL, VLDL, IDL, and Lp(a).

Question 17: The FOURIER trial demonstrated which key finding regarding PCSK9 inhibitor therapy (evolocumab)?

Evolocumab reduced mortality but not non-fatal MI rates
Evolocumab was superior to ezetimibe but not to high-intensity statins
Evolocumab increased the risk of new-onset diabetes significantly
Evolocumab reduced LDL-C by ~60% and significantly reduced cardiovascular events vs placebo on background statin (Correct answer)

Correct answer: Evolocumab reduced LDL-C by ~60% and significantly reduced cardiovascular events vs placebo on background statin

FOURIER showed evolocumab reduced LDL-C by ~59% and significantly reduced the composite of CV death, MI, stroke, hospitalization for unstable angina, and coronary revascularization.

Question 18: Which LDL-C threshold in an adult without other risk factors most strongly suggests homozygous FH rather than heterozygous FH?

LDL-C >160 mg/dL
LDL-C >250 mg/dL
LDL-C >400 mg/dL (Correct answer)
LDL-C >190 mg/dL

Correct answer: LDL-C >400 mg/dL

Untreated LDL-C levels exceeding 400 mg/dL (often 500-1000 mg/dL) are characteristic of homozygous FH, whereas heterozygous FH typically presents with LDL-C of 190-400 mg/dL.

Question 19: A patient on a high-intensity statin has a follow-up LDL-C of 58 mg/dL (down from 142 mg/dL at baseline). How should this response be interpreted?

Inadequate response; high-intensity statin should be replaced with ezetimibe
Inadequate response; a ≥75% reduction is required for all statin-treated patients
Adequate response; high-intensity statin should achieve ≥50% LDL-C reduction (Correct answer)
Excellent response but LDL-C below 50 mg/dL raises safety concerns requiring dose reduction

Correct answer: Adequate response; high-intensity statin should achieve ≥50% LDL-C reduction

High-intensity statin therapy is expected to lower LDL-C by ≥50%; this patient achieved a 59% reduction, which is a satisfactory pharmacologic response.

Question 20: Which lipoprotein is the major carrier of triglycerides in the fasting state?

VLDL (Correct answer)
HDL
Chylomicrons
LDL

Correct answer: VLDL

In the fasting state, VLDL produced by the liver is the predominant triglyceride-carrying lipoprotein, as intestinal chylomicron production ceases after an overnight fast.

Question 21: Which statin is FDA-approved for use in children as young as 8 years of age with heterozygous FH?

Atorvastatin
Simvastatin
Pravastatin (Correct answer)
Rosuvastatin

Correct answer: Pravastatin

Pravastatin is approved for children aged 8 and older with heterozygous familial hypercholesterolemia.

Question 22: In the REDUCE-IT trial, icosapentaenoic acid (EPA) 4 g/day reduced major cardiovascular events by approximately what percentage in statin-treated patients with elevated triglycerides?

25% (Correct answer)
10%
40%
5%

Correct answer: 25%

REDUCE-IT demonstrated a 25% relative risk reduction in major adverse cardiovascular events with 4 g/day EPA in statin-treated patients with TG 135–499 mg/dL.

Question 23: Statin-associated autoimmune myopathy (SAAM) differs from typical SAMS because it is characterized by which finding?

Persistent myopathy with anti-HMGCR antibodies after statin cessation (Correct answer)
Normal CK with severe subjective fatigue and cramps
Resolution of symptoms within 2 weeks of statin discontinuation
Myopathy exclusively in patients on high-intensity statin doses

Correct answer: Persistent myopathy with anti-HMGCR antibodies after statin cessation

SAAM is an immune-mediated necrotizing myopathy driven by anti-HMGCR autoantibodies that persists and may worsen even after statin discontinuation, requiring immunosuppressive treatment.

Question 24: For a child with suspected homozygous FH, at what age should LDL apheresis typically be initiated if LDL-C remains severely elevated despite maximal medical therapy?

By age 5
At birth
By age 10-12 (Correct answer)
Only after age 18

Correct answer: By age 10-12

Guidelines recommend initiating LDL apheresis by age 10-12 in HoFH patients with inadequate response to pharmacotherapy to prevent early cardiovascular events.

Question 25: Lp(a) levels are measured separately from a standard lipid panel. What is the primary clinical reason to order Lp(a)?

To assess response to statin therapy over time
To guide fibrate therapy selection in hypertriglyceridemia
To identify a genetically determined residual ASCVD risk factor not captured by standard lipid panel (Correct answer)
To calculate a more accurate LDL-C when triglycerides are elevated

Correct answer: To identify a genetically determined residual ASCVD risk factor not captured by standard lipid panel

Lp(a) is a genetically determined, largely statin-unresponsive lipoprotein that represents an independent ASCVD risk factor, and its measurement identifies residual risk missed by standard lipid panels.

Question 26: Which of the following Lp(a) levels is considered markedly elevated and an independent ASCVD risk factor that may prompt more aggressive LDL-C goals in FH patients?

>100 mg/dL
>50 mg/dL (Correct answer)
>30 mg/dL
>200 mg/dL

Correct answer: >50 mg/dL

Lp(a) >50 mg/dL (>125 nmol/L) is considered markedly elevated and an independent cardiovascular risk enhancer per ACC/AHA guidelines.

Question 27: How does lifestyle modification & nutrition counseling contribute to professional excellence in CLS certification?

It benefits organizations but not individual practitioners
It enhances competency, improves outcomes, and supports continuous professional growth (Correct answer)
It only matters during certification exams
It has no measurable impact on practice

Correct answer: It enhances competency, improves outcomes, and supports continuous professional growth

Lifestyle Modification & Nutrition Counseling is integral to CLS professional excellence, directly enhancing competency and driving measurable improvement in practice outcomes.

Question 28: Eruptive xanthomas appearing suddenly over the buttocks and extensor surfaces in a young man are most consistent with severe elevation of which lipoprotein?

Chylomicrons and/or VLDL (TG > 1000 mg/dL) (Correct answer)
Lp(a) above 150 nmol/L
IDL in Type III hyperlipidemia
LDL-C above 300 mg/dL

Correct answer: Chylomicrons and/or VLDL (TG > 1000 mg/dL)

Eruptive xanthomas are pathognomonic of extreme hypertriglyceridemia (TG >1000 mg/dL) due to chylomicron and/or VLDL excess causing tissue lipid deposition.

Question 29: Which condition is associated with elevated LDL levels?

Cardiovascular disease (Correct answer)
Anemia
Liver failure
Osteoporosis

Correct answer: Cardiovascular disease

Elevated levels of LDL (Low-Density Lipoprotein) cholesterol are a major risk factor for cardiovascular disease. High LDL contributes to the formation of atherosclerotic plaque in the arteries, which can narrow them and impede blood flow, leading to conditions like heart attack and stroke. Managing LDL levels is crucial for preventing these diseases.

Question 30: Autosomal recessive hypercholesterolemia (ARH) differs from classic FH in that it is caused by mutations in which gene?

APOB
PCSK9
LDLR
LDLRAP1 (Correct answer)

Correct answer: LDLRAP1

ARH results from loss-of-function mutations in LDLRAP1 (LDL receptor adaptor protein 1), which is required for hepatic but not peripheral tissue LDL receptor internalization.

Question 31: A 58-year-old woman with ASCVD and statin myalgia is started on bempedoic acid/ezetimibe combination tablet. Which statement best describes the additive mechanism?

Both agents inhibit HMG-CoA reductase at different binding sites
Bempedoic acid reduces hepatic synthesis while ezetimibe blocks intestinal cholesterol absorption via NPC1L1 (Correct answer)
Ezetimibe inhibits PCSK9 while bempedoic acid reduces LDL receptor degradation
Both agents inhibit cholesterol absorption at different intestinal transporters

Correct answer: Bempedoic acid reduces hepatic synthesis while ezetimibe blocks intestinal cholesterol absorption via NPC1L1

The complementary mechanisms—hepatic synthesis inhibition by bempedoic acid and intestinal absorption inhibition by ezetimibe via NPC1L1—produce additive LDL-C lowering.

Question 32: Which behavior change technique is most effective when helping a patient identify and overcome barriers to physical activity?

Telling the patient that exercise is non-negotiable and prescribing a mandatory regimen
Problem-solving specific barriers collaboratively and creating an action plan with contingencies (Correct answer)
Providing a brochure on the benefits of exercise without discussion
Scheduling lab tests more frequently to pressure the patient into compliance

Correct answer: Problem-solving specific barriers collaboratively and creating an action plan with contingencies

Collaborative problem-solving and action planning with contingency strategies (implementation intentions) significantly improve exercise adoption by addressing real-world obstacles.

Question 33: Statin-associated muscle symptoms (SAMS) are most accurately defined as which of the following?

Myopathy confirmed by muscle biopsy showing mitochondrial rarefaction
A spectrum from myalgia without CK elevation to rhabdomyolysis with CK >10× ULN (Correct answer)
Any myalgia occurring within 4 weeks of statin initiation regardless of CK level
Muscle pain exclusively linked to CK elevation above 3× the upper limit of normal

Correct answer: A spectrum from myalgia without CK elevation to rhabdomyolysis with CK >10× ULN

SAMS encompasses the full spectrum from mild myalgia (normal CK) through myositis (CK elevation) to life-threatening rhabdomyolysis (CK >10× ULN with renal injury).

Question 34: In a patient with metabolic syndrome, which lipid panel pattern is the classic triad?

Isolated LDL-C elevation >190 mg/dL with normal TG and HDL-C
Elevated LDL-C, elevated HDL-C, normal TG
High TG, low HDL-C, and small dense LDL particles (often normal or mildly elevated LDL-C) (Correct answer)
Elevated Lp(a) with borderline LDL-C

Correct answer: High TG, low HDL-C, and small dense LDL particles (often normal or mildly elevated LDL-C)

Metabolic syndrome dyslipidemia is characterized by hypertriglyceridemia, low HDL-C, and predominance of small dense LDL particles, with total LDL-C often only mildly elevated despite high particle number.

Question 35: Nascent HDL (pre-beta HDL) acquires free cholesterol from peripheral cells primarily through which transporter?

PCSK9
LDL receptor
SR-BI
ABCA1 (Correct answer)

Correct answer: ABCA1

ABCA1 (ATP-binding cassette transporter A1) mediates efflux of free cholesterol and phospholipids from cells to lipid-poor ApoA-I, forming nascent HDL particles.

Question 36: What role does smoking cessation play in cardiovascular risk?

Reduces cardiovascular risk (Correct answer)
Increases HDL
No effect on risk
Raises triglycerides

Correct answer: Reduces cardiovascular risk

Smoking cessation significantly reduces cardiovascular risk by improving endothelial function, decreasing inflammation, and lowering blood pressure and heart rate. Within just a few years of quitting, the risk of heart attack and stroke drops substantially, eventually approaching that of a non-smoker. It is one of the most impactful lifestyle changes for cardiovascular health.

Question 37: Which secondary cause of dyslipidemia classically produces elevated triglycerides and decreased HDL-C (type IV pattern)?

Primary biliary cholangitis
Hypothyroidism
Poorly controlled type 2 diabetes mellitus (Correct answer)
Nephrotic syndrome

Correct answer: Poorly controlled type 2 diabetes mellitus

Poorly controlled type 2 diabetes causes insulin resistance that increases VLDL production and reduces lipoprotein lipase activity, leading to elevated TG, low HDL-C, and small dense LDL—a classic type IV pattern.

Question 38: Which lipid value is most important for cardiovascular risk reduction?

HDL cholesterol
Total cholesterol
LDL cholesterol (Correct answer)
Triglycerides

Correct answer: LDL cholesterol

LDL (Low-Density Lipoprotein) cholesterol, often called "bad" cholesterol, is considered the most important lipid value for cardiovascular risk reduction. High levels of LDL cholesterol contribute directly to the formation of atherosclerotic plaques in arteries, which can lead to heart attacks and strokes. Therefore, lowering LDL cholesterol is a primary target in cardiovascular disease prevention and management.

Question 39: What does a coronary artery calcium (CAC) score of zero add to lipid panel interpretation for an intermediate-risk patient?

Indicates the patient has familial hypercholesterolemia and needs genetic testing
Suggests HDL-C measurement was erroneous and requires direct assay
Confirms that statin therapy should be initiated immediately regardless of lipid values
Identifies a low-risk group that may safely defer statin therapy and intensify lifestyle modification (Correct answer)

Correct answer: Identifies a low-risk group that may safely defer statin therapy and intensify lifestyle modification

A CAC score of zero in an intermediate-risk patient indicates very low near-term ASCVD event risk and supports deferral of statin therapy with aggressive lifestyle modification and reassessment.

Question 40: In patients undergoing solid organ transplantation on cyclosporine, which statin interaction is most clinically significant?

The interaction only affects pravastatin
Cyclosporine lowers statin levels, requiring dose increases
Only fibrates interact with cyclosporine
Cyclosporine markedly increases statin levels by inhibiting CYP3A4 and OATP1B1, increasing myopathy risk (Correct answer)

Correct answer: Cyclosporine markedly increases statin levels by inhibiting CYP3A4 and OATP1B1, increasing myopathy risk

Cyclosporine inhibits both CYP3A4 and OATP1B1 transporters, dramatically increasing systemic statin exposure and myopathy/rhabdomyolysis risk.

Question 41: Which dietary intervention has the strongest evidence for reducing LDL-C as an adjunct to pharmacotherapy in FH patients?

Intermittent fasting with caloric restriction
Omega-3 fatty acid supplementation >4 g/day
High-protein, very-low-carbohydrate ketogenic diet
Replacing saturated fats with unsaturated fats and reducing dietary cholesterol (Correct answer)

Correct answer: Replacing saturated fats with unsaturated fats and reducing dietary cholesterol

Reducing saturated fat intake and replacing it with unsaturated fats, combined with lowering dietary cholesterol, produces the greatest dietary LDL-C reduction in FH patients.

Question 42: What is the relationship between familial hypercholesterolemia management and overall Clinical Lipid Specialist Certification professional competency?

It is an essential component that strengthens the overall competency framework (Correct answer)
They are completely unrelated areas
It is a minor supplementary skill
It only applies to senior practitioners

Correct answer: It is an essential component that strengthens the overall competency framework

Familial Hypercholesterolemia Management is an essential component of the CLS competency framework, strengthening overall professional capability and credibility.

Question 43: When counseling a patient on the Therapeutic Lifestyle Changes (TLC) diet, what is the recommended daily dietary cholesterol limit?

500 mg/day
Less than 200 mg/day (Correct answer)
No specific limit is set; saturated fat is the only concern
300 mg/day

Correct answer: Less than 200 mg/day

The NCEP ATP III TLC diet recommends limiting dietary cholesterol to less than 200 mg/day, with saturated fat below 7% of total calories.

Question 44: A 45-year-old man has LDL-C 195 mg/dL, normal TG, normal HDL-C, no secondary causes, and a family history of premature ASCVD. According to the Dutch Lipid Clinic Network criteria, what diagnosis is most likely?

Heterozygous familial hypercholesterolemia (Correct answer)
Familial combined hyperlipidemia
Type IIb hyperlipoproteinemia
Polygenic hypercholesterolemia

Correct answer: Heterozygous familial hypercholesterolemia

The combination of LDL-C ≥190 mg/dL, absence of secondary causes, and family history of premature ASCVD meets diagnostic criteria for heterozygous familial hypercholesterolemia using the Dutch Lipid Clinic Network scoring system.

Question 45: A 55-year-old man has an LDL-C of 195 mg/dL on no therapy and no other cardiovascular risk factors. According to ACC/AHA guidelines, what is the most appropriate next step?

Initiate high-intensity statin without further evaluation
Start low-intensity statin and recheck in 12 months
Calculate 10-year ASCVD risk and use risk-benefit discussion to guide statin decision (Correct answer)
Refer for coronary calcium scoring before any therapy

Correct answer: Calculate 10-year ASCVD risk and use risk-benefit discussion to guide statin decision

LDL-C 160–189 mg/dL without other major risk factors requires calculating 10-year ASCVD risk and shared decision-making before statin initiation.

Question 46: In patients with type 2 diabetes mellitus, which lipid abnormality is MOST characteristic?

Markedly elevated LDL-C
Elevated triglycerides, low HDL-C, and small dense LDL particles (Correct answer)
Elevated Lp(a) with normal TG
Isolated HDL reduction with normal TG

Correct answer: Elevated triglycerides, low HDL-C, and small dense LDL particles

T2DM classically produces the 'diabetic dyslipidemia' triad: elevated triglycerides, low HDL-C, and a predominance of small dense LDL particles.

Question 47: Which of the following dietary modifications has the greatest evidence for reducing LDL-C in a non-pharmacologic patient education program?

Eliminating all dietary fat
Increasing dietary fiber and reducing saturated fat intake (Correct answer)
Doubling protein intake from animal sources
Switching to a carnivore diet

Correct answer: Increasing dietary fiber and reducing saturated fat intake

Increasing soluble fiber and reducing saturated fat are the most evidence-based dietary strategies to lower LDL-C.

Question 48: Which enzyme esterifies free cholesterol within HDL particles to form cholesteryl esters?

Hepatic lipase
Phospholipid transfer protein
LCAT (Correct answer)
CETP

Correct answer: LCAT

Lecithin-cholesterol acyltransferase (LCAT) is activated by ApoA-I and esterifies free cholesterol in HDL, trapping it in the particle core and driving cholesterol efflux from tissues.

Question 49: How should CLS professionals measure success in lifestyle modification & nutrition counseling?

Success measurement is not applicable
By comparing only to minimum requirements
Through subjective self-assessment only
Using defined metrics, benchmarks, and regular evaluation against established goals (Correct answer)

Correct answer: Using defined metrics, benchmarks, and regular evaluation against established goals

Success in lifestyle modification & nutrition counseling is measured through defined metrics and benchmarks, with regular evaluation against established professional goals.

Question 50: Which condition is characterized by extremely low or absent LDL-C due to a mutation in apolipoprotein B?

Abetalipoproteinemia and hypobetalipoproteinemia (Correct answer)
Smith-Lemli-Opitz syndrome
Tangier disease
Familial dysbetalipoproteinemia

Correct answer: Abetalipoproteinemia and hypobetalipoproteinemia

Abetalipoproteinemia (MTP mutations) and familial hypobetalipoproteinemia (APOB mutations) both result in absent or markedly reduced ApoB-containing lipoprotein production and very low LDL-C.

Question 51: Niemann-Pick C1-Like 1 (NPC1L1) protein is the target of which lipid-lowering medication?

Niacin
Ezetimibe (Correct answer)
Fenofibrate
Evolocumab

Correct answer: Ezetimibe

Ezetimibe inhibits NPC1L1, the intestinal transporter responsible for absorbing dietary and biliary cholesterol, reducing cholesterol delivery to the liver and lowering LDL-C by 15-20%.

Question 52: What is the relationship between patient education & adherence and overall Clinical Lipid Specialist Certification professional competency?

It is an essential component that strengthens the overall competency framework (Correct answer)
It is a minor supplementary skill
It only applies to senior practitioners
They are completely unrelated areas

Correct answer: It is an essential component that strengthens the overall competency framework

Patient Education & Adherence is an essential component of the CLS competency framework, strengthening overall professional capability and credibility.

Question 53: A patient with established ASCVD and LDL-C of 95 mg/dL on high-intensity statin is being considered for ezetimibe. The primary rationale based on IMPROVE-IT trial is:

Ezetimibe prevents statin myopathy by competitive inhibition
Ezetimibe reduces triglycerides more effectively than statins
Ezetimibe has pleiotropic anti-inflammatory effects beyond LDL-C lowering
Further lowering LDL-C with ezetimibe modestly but significantly reduces cardiovascular events (Correct answer)

Correct answer: Further lowering LDL-C with ezetimibe modestly but significantly reduces cardiovascular events

IMPROVE-IT demonstrated that adding ezetimibe to simvastatin further reduced LDL-C and produced a modest but significant reduction in cardiovascular events.

Question 54: Which counseling technique involves asking patients to repeat back key education points in their own words to assess understanding?

Teach-back method (Correct answer)
Shared decision-making
Brief action planning
Motivational interviewing

Correct answer: Teach-back method

The teach-back method verifies patient comprehension by having them explain information in their own words.

Question 55: Which pharmacokinetic property of fluvastatin distinguishes it from most other statins in terms of CYP450 metabolism?

It is primarily metabolized by CYP2C9 (Correct answer)
It is primarily metabolized by CYP3A4
It bypasses hepatic first-pass metabolism entirely
It is an OATP1B1 substrate but not a CYP substrate

Correct answer: It is primarily metabolized by CYP2C9

Fluvastatin is predominantly metabolized by CYP2C9, making it susceptible to interactions with CYP2C9 inhibitors such as fluconazole rather than with CYP3A4 inhibitors.

Question 56: At what age does the American Academy of Pediatrics recommend universal lipid screening for children?

Age 3-5 years
Age 9-11 years (Correct answer)
Age 6-8 years
Age 12-14 years

Correct answer: Age 9-11 years

Universal lipid screening is recommended for all children at ages 9-11 years and again at ages 17-21 years.

Question 57: What is a key principle of patient education & adherence in Clinical Lipid Specialist Certification practice?

Relying solely on personal experience
Applying structured methodologies based on evidence and best practices (Correct answer)
Avoiding all standardized approaches
Minimizing documentation requirements

Correct answer: Applying structured methodologies based on evidence and best practices

Patient Education & Adherence in Clinical Lipid Specialist Certification practice requires applying structured, evidence-based methodologies while adapting to specific professional contexts.

Question 58: Coenzyme Q10 (ubiquinone) supplementation has been proposed for statin-induced myalgia based on which pharmacologic rationale?

CoQ10 directly inhibits HMGCR rebound expression induced by statins
Statins upregulate CoQ10 synthesis via an independent pathway requiring supplementation
CoQ10 accelerates CYP3A4-mediated statin metabolism, reducing plasma levels
Statins inhibit the mevalonate pathway, reducing CoQ10 biosynthesis alongside cholesterol (Correct answer)

Correct answer: Statins inhibit the mevalonate pathway, reducing CoQ10 biosynthesis alongside cholesterol

Because CoQ10 is synthesized downstream of mevalonate via the same pathway statins block, statin use can reduce CoQ10 levels, potentially contributing to mitochondrial dysfunction in muscle.

Question 59: A CLS is reviewing a lipid panel in a patient taking niacin. Which expected lipid change is most characteristic of niacin therapy?

Significant reduction in LDL-C with minimal HDL-C change
Reduction in TG only with no effect on HDL-C or LDL-C
Increase in HDL-C with paradoxical increase in LDL-C
Marked increase in HDL-C and reduction in both TG and LDL-C (Correct answer)

Correct answer: Marked increase in HDL-C and reduction in both TG and LDL-C

Niacin has the broadest lipid effect profile: it raises HDL-C most significantly (15–35%), reduces TG (20–50%), and modestly reduces LDL-C (5–25%), making it unique among lipid-modifying agents.

Question 60: During motivational interviewing for statin adherence, what is the clinician's primary role?

To document non-adherence in the medical record as a liability measure
To provide extensive educational lectures about lipid physiology
To persuade and direct the patient toward medication compliance
To elicit the patient's own motivations for change and resolve ambivalence collaboratively (Correct answer)

Correct answer: To elicit the patient's own motivations for change and resolve ambivalence collaboratively

Motivational interviewing is patient-centered, eliciting the patient's intrinsic motivations rather than using persuasion or education alone.

Question 61: What is the goal of antihypertensive therapy in cardiovascular risk?

Raise HDL
Reduce stroke and heart attack risk (Correct answer)
Increase cardiac output
Improve sleep

Correct answer: Reduce stroke and heart attack risk

The primary goal of antihypertensive therapy is to lower elevated blood pressure, thereby reducing the strain on the cardiovascular system. By achieving and maintaining healthy blood pressure levels, the risk of serious cardiovascular events such as stroke, heart attack, heart failure, and kidney disease is significantly decreased. This protective effect is central to long-term cardiovascular health.

Question 62: Which enzyme converts arachidonic acid to thromboxane A2, which promotes platelet aggregation?

Phospholipase A2
Prostacyclin synthase
Lipoxygenase
Cyclooxygenase (COX) (Correct answer)

Correct answer: Cyclooxygenase (COX)

Cyclooxygenase (COX-1 and COX-2) converts arachidonic acid to prostaglandin H2, which is then converted to thromboxane A2 by thromboxane synthase in platelets, promoting platelet aggregation and vasoconstriction.

Question 63: How does secondary causes of dyslipidemia contribute to professional excellence in CLS certification?

It enhances competency, improves outcomes, and supports continuous professional growth (Correct answer)
It benefits organizations but not individual practitioners
It only matters during certification exams
It has no measurable impact on practice

Correct answer: It enhances competency, improves outcomes, and supports continuous professional growth

Secondary Causes of Dyslipidemia is integral to CLS professional excellence, directly enhancing competency and driving measurable improvement in practice outcomes.

Question 64: Which of the following best describes the mechanism of bempedoic acid's LDL-C lowering effect?

It directly upregulates LDL receptor expression via SREBP-2 pathway
It activates LXR receptors to promote reverse cholesterol transport
It inhibits ATP-citrate lyase, reducing hepatic cholesterol synthesis upstream of HMG-CoA reductase (Correct answer)
It inhibits intestinal cholesterol absorption via NPC1L1 transporter blockade

Correct answer: It inhibits ATP-citrate lyase, reducing hepatic cholesterol synthesis upstream of HMG-CoA reductase

Bempedoic acid inhibits ATP-citrate lyase, an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway, reducing hepatic cholesterol production.

Question 65: How should CLS professionals measure success in novel lipid-lowering therapies?

Using defined metrics, benchmarks, and regular evaluation against established goals (Correct answer)
Through subjective self-assessment only
Success measurement is not applicable
By comparing only to minimum requirements

Correct answer: Using defined metrics, benchmarks, and regular evaluation against established goals

Success in novel lipid-lowering therapies is measured through defined metrics and benchmarks, with regular evaluation against established professional goals.

Question 66: How does statin therapy & pharmacology contribute to professional excellence in CLS certification?

It only matters during certification exams
It has no measurable impact on practice
It enhances competency, improves outcomes, and supports continuous professional growth (Correct answer)
It benefits organizations but not individual practitioners

Correct answer: It enhances competency, improves outcomes, and supports continuous professional growth

Statin Therapy & Pharmacology is integral to CLS professional excellence, directly enhancing competency and driving measurable improvement in practice outcomes.

Question 67: What lifestyle factor improves cardiovascular health?

Excess alcohol
Physical activity (Correct answer)
High-sugar diet
Tobacco use

Correct answer: Physical activity

Regular physical activity is a cornerstone of cardiovascular health. It helps lower blood pressure, improve cholesterol levels, manage weight, and enhance insulin sensitivity, all of which reduce the risk of heart disease and stroke. Engaging in moderate-intensity aerobic exercise most days of the week is highly recommended.

Question 68: A patient reports eating salmon twice weekly. Which additional dietary fish recommendation would best increase omega-3 intake while minimizing mercury exposure?

Adding swordfish or king mackerel three times weekly
Including sardines, herring, or mackerel (Atlantic) as additional low-mercury fatty fish options (Correct answer)
Consuming tuna steaks daily for their high DHA content
Replacing salmon with tilapia as a higher omega-3 source

Correct answer: Including sardines, herring, or mackerel (Atlantic) as additional low-mercury fatty fish options

Sardines, herring, and Atlantic mackerel are small fatty fish rich in EPA+DHA with low bioaccumulation of methylmercury, making them ideal additions to a heart-healthy diet.

Question 69: Colesevelam (Welchol) has which unique advantage over older bile acid sequestrants like cholestyramine?

Improved glycemic control in type 2 diabetes (Correct answer)
Does not interfere with fat-soluble vitamin absorption
Can be used in patients with hypertriglyceridemia
Greater LDL-C reduction

Correct answer: Improved glycemic control in type 2 diabetes

Colesevelam is FDA-approved as an adjunct to improve glycemic control in type 2 diabetes in addition to its LDL-C–lowering effect.

Question 70: A patient with diabetes mellitus aged 40–75 years and LDL-C 70–189 mg/dL but no other major risk factors should receive which statin intensity?

No statin therapy unless ASCVD risk >20%
High-intensity statin plus ezetimibe
Moderate-intensity statin (Correct answer)
Low-intensity statin

Correct answer: Moderate-intensity statin

Per 2018 ACC/AHA guidelines, diabetic patients aged 40–75 with LDL-C 70–189 mg/dL qualify for at least moderate-intensity statin therapy.

Question 71: In a child with nephrotic syndrome, which lipid abnormality is most characteristically elevated?

HDL-C
LDL-C and VLDL (Correct answer)
Apolipoprotein A-I
Lipoprotein(a)

Correct answer: LDL-C and VLDL

Nephrotic syndrome causes hepatic overproduction of VLDL and decreased LDL catabolism, markedly elevating LDL-C and VLDL.

Question 72: A patient with diabetes and hypertriglyceridemia is counseled on diet. Which carbohydrate-related recommendation is most important?

Limit total carbohydrate intake and avoid added sugars and fructose-containing beverages (Correct answer)
Eat as many complex carbohydrates as desired since they don't affect triglycerides
Increase refined carbohydrate intake to spare dietary fat
Replace starchy vegetables with fruit juice as a healthier carbohydrate source

Correct answer: Limit total carbohydrate intake and avoid added sugars and fructose-containing beverages

In diabetic hypertriglyceridemia, reducing total carbohydrates and eliminating added sugars and fructose is critical as hepatic de novo lipogenesis from excess carbohydrates drives VLDL overproduction.

Question 73: A postmenopausal woman starts oral estrogen-based hormone therapy. Which lipid panel change is most expected?

Both LDL-C and TG decrease with no change in HDL-C
LDL-C decreases and TG increases (Correct answer)
LDL-C increases and HDL-C decreases
HDL-C decreases and LDL-C remains unchanged

Correct answer: LDL-C decreases and TG increases

Oral estrogen decreases LDL-C by upregulating hepatic LDL receptors but increases triglycerides by stimulating hepatic VLDL synthesis, a pattern that can exacerbate pre-existing hypertriglyceridemia.

Question 74: When implementing lifestyle modification & nutrition counseling practices, what should CLS professionals prioritize?

Personal preferences and comfort level
Alignment with professional standards, stakeholder needs, and organizational goals (Correct answer)
Speed of implementation above all else
Cost reduction as the sole objective

Correct answer: Alignment with professional standards, stakeholder needs, and organizational goals

Effective implementation of lifestyle modification & nutrition counseling requires balancing professional standards, stakeholder needs, and organizational objectives for optimal results.

Question 75: What is the recommended aerobic exercise target per week for cardiovascular risk reduction in most adults according to major guidelines?

75 minutes of vigorous-intensity or 150 minutes of moderate-intensity activity (Correct answer)
20 minutes of vigorous activity 2 days per week
30 minutes of light stretching on most days
60 minutes of moderate activity on weekends only

Correct answer: 75 minutes of vigorous-intensity or 150 minutes of moderate-intensity activity

Current guidelines recommend at least 150 minutes/week of moderate-intensity or 75 minutes/week of vigorous-intensity aerobic activity for cardiovascular risk reduction.

Question 76: A patient following a very-low-carbohydrate ketogenic diet shows elevated LDL-C on labs. What is the most likely explanation?

Low carbohydrate intake directly inhibits LDL receptor expression
Ketones suppress bile acid synthesis, reducing LDL clearance
High saturated fat intake common in ketogenic diets upregulates LDL receptor degradation (Correct answer)
Ketosis directly stimulates hepatic VLDL overproduction

Correct answer: High saturated fat intake common in ketogenic diets upregulates LDL receptor degradation

High saturated fat consumption typical of ketogenic diets increases hepatic PCSK9 activity and reduces LDL receptor expression, leading to elevated plasma LDL-C.

Question 77: Which of the following is considered a 'risk-enhancing factor' that may favor initiating statin therapy in a borderline-risk patient?

BMI of 27 kg/m²
HDL-C of 55 mg/dL
Family history of premature ASCVD in a first-degree relative before age 55 (men) or 65 (women) (Correct answer)
LDL-C of 80 mg/dL

Correct answer: Family history of premature ASCVD in a first-degree relative before age 55 (men) or 65 (women)

Family history of premature ASCVD is one of the ACC/AHA risk-enhancing factors that can tip the risk-benefit discussion toward statin initiation.

Question 78: In secondary prevention, the 2018 ACC/AHA guidelines define 'very high-risk ASCVD' patients as those with major ASCVD events plus which additional criteria?

LDL-C >130 mg/dL on statin therapy
Major ASCVD events plus high-risk conditions such as multiple events or diabetes (Correct answer)
Age >75 years only
History of statin intolerance

Correct answer: Major ASCVD events plus high-risk conditions such as multiple events or diabetes

Very high-risk ASCVD is defined by multiple major ASCVD events or one major event plus high-risk conditions (e.g., diabetes, CKD, familial hypercholesterolemia, smoking).

Question 79: Which patient population is excluded from the Pooled Cohort Equations because the tool was not validated in this group?

Patients with type 2 diabetes
Patients aged 20–39 or >79 years (Correct answer)
Adults aged 40–75 years
Patients with hypertension on antihypertensive therapy

Correct answer: Patients aged 20–39 or >79 years

The Pooled Cohort Equations are validated for adults aged 40–79; alternative approaches are needed for those younger or older.

Question 80: Which cooking oil substitution best supports LDL reduction in a patient following a heart-healthy diet?

Replacing butter with olive oil (Correct answer)
Replacing canola oil with lard
Replacing olive oil with palm oil
Replacing butter with coconut oil

Correct answer: Replacing butter with olive oil

Replacing saturated fats (butter) with monounsaturated fats (olive oil) reduces LDL-C without adversely affecting HDL-C.

Question 81: Which physical finding is pathognomonic for homozygous familial hypercholesterolemia in children?

Corneal arcus
Planar xanthomas in the interdigital web spaces (Correct answer)
Xanthelasma
Eruptive xanthomas

Correct answer: Planar xanthomas in the interdigital web spaces

Planar or tuberous xanthomas over the hands, elbows, knees, and interdigital spaces are hallmark findings in homozygous FH.

Question 82: A patient with HoFH caused by two null LDLR mutations would be expected to have what residual LDL receptor activity?

25-50% of normal
0-2% of normal (Correct answer)
50-75% of normal
10-25% of normal

Correct answer: 0-2% of normal

Receptor-negative HoFH (two null mutations) results in <2% residual LDL receptor activity, producing the most severe LDL elevation and poorest response to statins.

Question 83: What is the relationship between lipid panel interpretation and overall Clinical Lipid Specialist Certification professional competency?

It is a minor supplementary skill
It is an essential component that strengthens the overall competency framework (Correct answer)
They are completely unrelated areas
It only applies to senior practitioners

Correct answer: It is an essential component that strengthens the overall competency framework

Lipid Panel Interpretation is an essential component of the CLS competency framework, strengthening overall professional capability and credibility.

Question 84: What is a key principle of pediatric lipid disorders in Clinical Lipid Specialist Certification practice?

Relying solely on personal experience
Applying structured methodologies based on evidence and best practices (Correct answer)
Minimizing documentation requirements
Avoiding all standardized approaches

Correct answer: Applying structured methodologies based on evidence and best practices

Pediatric Lipid Disorders in Clinical Lipid Specialist Certification practice requires applying structured, evidence-based methodologies while adapting to specific professional contexts.

Question 85: Ezetimibe lowers LDL-C in FH patients primarily through which mechanism?

Inhibiting HMG-CoA reductase in hepatocytes
Upregulating LDL receptor expression via LXR pathway
Blocking NPC1L1 transporter in intestinal enterocytes (Correct answer)
Increasing PCSK9 degradation

Correct answer: Blocking NPC1L1 transporter in intestinal enterocytes

Ezetimibe inhibits the NPC1L1 transporter at the brush border of intestinal enterocytes, reducing cholesterol absorption by approximately 50%.

Question 86: The ENHANCE trial studying high-dose simvastatin plus ezetimibe versus simvastatin alone in HeFH patients showed which unexpected result?

Greater carotid IMT regression with combination therapy
Higher rates of muscle toxicity in the combination group
Earlier onset of corneal arcus in the monotherapy group
No significant difference in carotid IMT despite additional LDL-C lowering with ezetimibe (Correct answer)

Correct answer: No significant difference in carotid IMT despite additional LDL-C lowering with ezetimibe

ENHANCE found no significant reduction in carotid intima-media thickness progression with ezetimibe add-on therapy despite greater LDL-C lowering, raising questions about surrogate endpoints.

Question 87: What challenge is most commonly encountered in lifestyle modification & nutrition counseling within Clinical Lipid Specialist Certification practice?

Lack of available training materials
Resistance to change and difficulty maintaining consistency across stakeholders (Correct answer)
Excessive regulatory support
Unlimited budget allocation

Correct answer: Resistance to change and difficulty maintaining consistency across stakeholders

The most common challenge in lifestyle modification & nutrition counseling is overcoming resistance to change while maintaining consistent implementation across diverse stakeholders.

Question 88: How should CLS professionals measure success in secondary causes of dyslipidemia?

By comparing only to minimum requirements
Success measurement is not applicable
Using defined metrics, benchmarks, and regular evaluation against established goals (Correct answer)
Through subjective self-assessment only

Correct answer: Using defined metrics, benchmarks, and regular evaluation against established goals

Success in secondary causes of dyslipidemia is measured through defined metrics and benchmarks, with regular evaluation against established professional goals.

Question 89: When implementing novel lipid-lowering therapies practices, what should CLS professionals prioritize?

Speed of implementation above all else
Cost reduction as the sole objective
Alignment with professional standards, stakeholder needs, and organizational goals (Correct answer)
Personal preferences and comfort level

Correct answer: Alignment with professional standards, stakeholder needs, and organizational goals

Effective implementation of novel lipid-lowering therapies requires balancing professional standards, stakeholder needs, and organizational objectives for optimal results.

Question 90: A child of two parents with heterozygous FH has what probability of inheriting homozygous FH?

100%
75%
25% (Correct answer)
50%

Correct answer: 25%

With both parents carrying one FH allele, Mendelian inheritance gives a 25% chance of inheriting both defective alleles.

Question 91: Which of the following best defines the LDL-C treatment goal for a patient with established ASCVD and a recent ACS event (very high-risk)?

<55 mg/dL (Correct answer)
<100 mg/dL
<40 mg/dL
<70 mg/dL

Correct answer: <55 mg/dL

For very high-risk ASCVD patients (including those with recent ACS), 2022 ACC/AHA guidelines recommend an LDL-C goal of <55 mg/dL with a ≥50% reduction from baseline.

Question 92: Which medication class is used as an adjunct to statins in children with familial hypercholesterolemia who need additional LDL-C lowering?

Niacin
Omega-3 fatty acids
Fibrates
Bile acid sequestrants (Correct answer)

Correct answer: Bile acid sequestrants

Bile acid sequestrants (e.g., colesevelam) are approved for pediatric use and provide additive LDL-C lowering with statins.

Question 93: Hepatic lipase (HL) plays a role in converting which lipoprotein to another?

IDL to LDL and HDL2 to HDL3 (Correct answer)
Chylomicrons to chylomicron remnants
VLDL to IDL
Nascent HDL to mature HDL

Correct answer: IDL to LDL and HDL2 to HDL3

Hepatic lipase hydrolyzes triglycerides and phospholipids in IDL (converting it to LDL) and in HDL2 (converting it to smaller, denser HDL3), playing a key role in both endogenous and reverse cholesterol transport pathways.

Question 94: A 45-year-old sedentary patient with mixed dyslipidemia asks which type of exercise most effectively lowers triglycerides. What is most accurate?

Short 5-minute walks several times daily are as effective as prolonged aerobic sessions
Flexibility exercises such as yoga are equally effective as aerobic exercise
Resistance training is superior to aerobic exercise for triglyceride reduction
Aerobic exercise of sufficient duration and intensity is most effective for lowering triglycerides (Correct answer)

Correct answer: Aerobic exercise of sufficient duration and intensity is most effective for lowering triglycerides

Sustained aerobic exercise increases lipoprotein lipase activity and reduces hepatic VLDL secretion, making it the most effective exercise modality for triglyceride reduction.

Question 95: Which of the following correctly describes a key pharmacokinetic difference between alirocumab (PCSK9 monoclonal antibody) and inclisiran (PCSK9 siRNA)?

Both drugs act extracellularly and have identical dosing schedules
Alirocumab reduces circulating PCSK9 protein; inclisiran prevents PCSK9 protein synthesis in hepatocytes (Correct answer)
Inclisiran directly binds and inhibits circulating PCSK9; alirocumab silences PCSK9 mRNA
Alirocumab is given orally; inclisiran is given IV every 3 months

Correct answer: Alirocumab reduces circulating PCSK9 protein; inclisiran prevents PCSK9 protein synthesis in hepatocytes

Alirocumab binds circulating PCSK9 protein to prevent receptor binding, while inclisiran enters hepatocytes and degrades PCSK9 mRNA, blocking synthesis at the source.

Question 96: A patient with type III hyperlipidemia (dysbetalipoproteinemia) has excess accumulation of which lipoprotein remnants?

Lp(a) and nascent HDL
VLDL remnants (IDL) and chylomicron remnants (Correct answer)
HDL2 and HDL3
LDL and Lp(a)

Correct answer: VLDL remnants (IDL) and chylomicron remnants

Type III hyperlipidemia (familial dysbetalipoproteinemia) results from ApoE2 homozygosity, which impairs hepatic clearance of IDL and chylomicron remnants, causing equal elevations of cholesterol and triglycerides.

Question 97: A patient with hypertriglyceridemia asks about alcohol consumption. What is the most appropriate recommendation?

Complete abstinence from alcohol is required
Alcohol has no meaningful impact on triglyceride levels
Limit to 1 drink/day for women and 2 drinks/day for men (Correct answer)
Red wine is acceptable because it raises HDL

Correct answer: Limit to 1 drink/day for women and 2 drinks/day for men

Moderate alcohol limits are advised for hypertriglyceridemia, but severe cases may require complete abstinence as alcohol markedly raises triglycerides.

Question 98: What stimulates the release of bile from the gallbladder?

Cholecystokinin (CCK) (Correct answer)
Thyroxine
Insulin
Glucagon

Correct answer: Cholecystokinin (CCK)

Cholecystokinin (CCK) is a hormone released by the small intestine in response to the presence of fats and proteins. It stimulates the contraction of the gallbladder, causing it to release bile into the small intestine. Bile is essential for the emulsification and digestion of dietary fats.

Question 99: Acromegaly most commonly causes which type of dyslipidemia?

Isolated elevated Lp(a)
Mixed hyperlipidemia with xanthomas
Hypertriglyceridemia with or without reduced HDL-C (Correct answer)
Isolated hypercholesterolemia

Correct answer: Hypertriglyceridemia with or without reduced HDL-C

Excess growth hormone in acromegaly promotes lipolysis and hepatic VLDL production, resulting primarily in hypertriglyceridemia.

Question 100: Bempedoic acid reduces LDL-C in FH patients by inhibiting ATP citrate lyase. Its key advantage over statins is that it:

Does not require dose adjustment in renal impairment
Lowers LDL-C more than high-intensity statins
Is activated only in the liver, minimizing muscle-related side effects (Correct answer)
Reduces Lp(a) by more than 50%

Correct answer: Is activated only in the liver, minimizing muscle-related side effects

Bempedoic acid requires hepatic activation by ACSVL1 and is not converted to its active form in muscle, reducing the risk of myopathy seen with statins.

Question 101: Which statement about FH and secondary prevention is correct?

PCSK9 inhibitors are not approved for FH patients who already have established ASCVD
FH patients with established ASCVD have the same LDL-C goals as non-FH ASCVD patients
FH patients with ASCVD are very-high-risk and should target LDL-C <55 mg/dL with >50% reduction (Correct answer)
Secondary prevention goals do not apply to FH patients under age 40

Correct answer: FH patients with ASCVD are very-high-risk and should target LDL-C <55 mg/dL with >50% reduction

FH patients with established ASCVD fall into the very-high-risk category per ACC/AHA guidelines, warranting an LDL-C goal of <55 mg/dL and at least 50% reduction from baseline.

Question 102: Volanesorsen is an antisense oligonucleotide (ASO) approved for which specific lipid disorder?

Familial hypercholesterolemia with LDL-C > 190 mg/dL
Familial chylomicronemia syndrome (FCS) due to lipoprotein lipase deficiency (Correct answer)
Primary prevention in patients with metabolic syndrome
Familial combined hyperlipidemia with mixed dyslipidemia

Correct answer: Familial chylomicronemia syndrome (FCS) due to lipoprotein lipase deficiency

Volanesorsen targets APOC3 mRNA to reduce apolipoprotein C-III levels, thereby enhancing triglyceride clearance in patients with FCS.

Question 103: Which statement about the ankle-brachial index (ABI) as a cardiovascular risk marker is correct?

ABI replaces stress testing for coronary evaluation
An ABI <0.9 is diagnostic of peripheral artery disease and signals elevated ASCVD risk (Correct answer)
An ABI >1.4 indicates low cardiovascular risk
ABI is only validated in women under 60

Correct answer: An ABI <0.9 is diagnostic of peripheral artery disease and signals elevated ASCVD risk

An ABI <0.9 indicates peripheral artery disease, which is an ASCVD risk equivalent that increases overall cardiovascular event risk.

Question 104: A patient on a Mediterranean diet reports eating 5 servings of fruits and vegetables daily. Which additional dietary change would most significantly further reduce cardiovascular risk?

Switching from whole grains to refined grains
Adding 2 tablespoons of ground flaxseed daily (Correct answer)
Increasing red meat to 5 servings per week
Adding full-fat dairy to each meal

Correct answer: Adding 2 tablespoons of ground flaxseed daily

Ground flaxseed provides alpha-linolenic acid (ALA) and soluble fiber, both of which contribute to LDL reduction and cardiovascular risk improvement.

Question 105: Mipomersen, an antisense oligonucleotide approved for HoFH, reduces apoB synthesis by targeting which molecule?

LDLR mRNA to increase receptor expression
APOB mRNA in hepatocytes (Correct answer)
PCSK9 mRNA in hepatocytes
MTP protein in the endoplasmic reticulum

Correct answer: APOB mRNA in hepatocytes

Mipomersen is an antisense oligonucleotide that hybridizes to APOB-100 mRNA, reducing its translation and thereby decreasing hepatic apoB and LDL production.

Question 106: A 7-year-old with type 1 diabetes presents with lipemia retinalis and TG of 2,800 mg/dL. Which enzyme deficiency is most likely?

Hepatic lipase deficiency
Lipoprotein lipase deficiency (Correct answer)
Lecithin-cholesterol acyltransferase deficiency
Cholesterol ester transfer protein deficiency

Correct answer: Lipoprotein lipase deficiency

Lipoprotein lipase (LPL) deficiency causes severe chylomicronemia with massively elevated triglycerides, often presenting in childhood.

Question 107: Why is weight management important in cardiovascular care?

It reduces bone density
It supports cardiovascular health (Correct answer)
It raises total cholesterol
It increases muscle mass

Correct answer: It supports cardiovascular health

Weight management is crucial for cardiovascular health because excess body weight, particularly obesity, is strongly linked to several cardiovascular risk factors. It can lead to higher blood pressure, unfavorable cholesterol levels, insulin resistance, and inflammation, all of which increase the risk of heart disease and stroke. Achieving and maintaining a healthy weight significantly improves these markers and overall cardiovascular well-being.

Question 108: The REDUCE-IT trial demonstrated significant cardiovascular risk reduction using which specific omega-3 product at 4 g/day?

Docosahexaenoic acid (DHA only)
Over-the-counter fish oil at 4 g/day
Icosapentaenoic acid (EPA only; Vascepa/icosapent ethyl) (Correct answer)
Omega-3 acid ethyl esters containing both EPA and DHA (Lovaza)

Correct answer: Icosapentaenoic acid (EPA only; Vascepa/icosapent ethyl)

REDUCE-IT showed that icosapentaenoic acid (EPA-only, Vascepa) at 4 g/day reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides and established cardiovascular disease or diabetes.

Question 109: A 45-year-old man with HoFH (no functional LDL receptors) is on maximum statin, ezetimibe, and PCSK9 inhibitor therapy but LDL-C remains 380 mg/dL. Which novel agent would most likely provide clinically meaningful LDL-C lowering in this scenario?

Inclisiran (PCSK9 siRNA)
Bempedoic acid (ACL inhibitor)
Evinacumab (ANGPTL3 inhibitor) (Correct answer)
Evolocumab (PCSK9 monoclonal antibody)

Correct answer: Evinacumab (ANGPTL3 inhibitor)

Evinacumab works independently of LDL receptor function by enhancing lipoprotein catabolism via LPL and EL disinhibition, making it effective in HoFH patients with non-functional receptors.

Question 110: Which behavioral strategy is most effective at sustaining long-term lipid medication adherence according to adherence literature?

Simplifying regimens, using reminders, and addressing patient-specific barriers collaboratively (Correct answer)
Giving patients detailed pharmacology textbooks
Threatening patients with consequences of non-adherence
Prescribing the maximum dose to ensure rapid results

Correct answer: Simplifying regimens, using reminders, and addressing patient-specific barriers collaboratively

Simplification, reminder systems, and collaborative problem-solving are the most evidence-supported strategies for sustained adherence.

Question 111: LDL apheresis in FH patients removes LDL-C by what approximate percentage per session?

40-50%
20-30%
60-75% (Correct answer)
85-95%

Correct answer: 60-75%

Each LDL apheresis session acutely reduces LDL-C by approximately 60-75%, though levels rebound between sessions, typically performed every 1-2 weeks.

Question 112: What is the primary treatment goal for high-risk cardiovascular patients?

LDL < 70 mg/dL (Correct answer)
LDL < 130 mg/dL
LDL < 160 mg/dL
LDL < 100 mg/dL

Correct answer: LDL < 70 mg/dL

For high-risk cardiovascular patients, such as those with established atherosclerotic cardiovascular disease or multiple major risk factors, aggressive LDL cholesterol lowering is recommended. An LDL goal of less than 70 mg/dL is often targeted to significantly reduce the risk of recurrent cardiovascular events. This stringent goal reflects the increased vulnerability of these patients.

Question 113: Which dietary pattern is most strongly associated with reduced non-HDL cholesterol and cardiovascular events in clinical trials?

High-protein, low-carbohydrate (Atkins) diet
Carnivore diet emphasizing animal proteins
Mediterranean diet rich in olive oil, fish, and vegetables (Correct answer)
Low-fat, high-refined-carbohydrate diet

Correct answer: Mediterranean diet rich in olive oil, fish, and vegetables

The Mediterranean diet has the strongest evidence base from randomized trials (e.g., PREDIMED) demonstrating reduced cardiovascular events and improved lipid profiles.

Question 114: What is the primary mechanism by which metabolic syndrome increases cardiovascular risk beyond individual risk factors?

Exclusive elevation of LDL-C particle size
Clustering of insulin resistance, dyslipidemia, hypertension, and central obesity causing additive risk (Correct answer)
Direct myocardial toxicity from hyperglycemia
Suppression of HDL synthesis in the liver

Correct answer: Clustering of insulin resistance, dyslipidemia, hypertension, and central obesity causing additive risk

Metabolic syndrome's risk stems from clustering of multiple interrelated abnormalities driven by insulin resistance, which additively amplifies ASCVD risk.

Question 115: What is the role of the liver in lipid metabolism?

Stores calcium
Produces red blood cells
Synthesizes and regulates lipids (Correct answer)
Breaks down hemoglobin

Correct answer: Synthesizes and regulates lipids

The liver plays a central and critical role in lipid metabolism. It is responsible for synthesizing cholesterol, triglycerides, and various lipoproteins, as well as processing and regulating the levels of these lipids in the body. This includes the production of bile acids, which aid in fat digestion.

Question 116: A patient with familial hypercholesterolemia asks if lifestyle changes alone can normalize their LDL-C. What is the most appropriate response?

Lifestyle changes alone are typically sufficient to normalize LDL-C in FH
Vigorous exercise can compensate for the LDL receptor defect in FH
Diet changes are ineffective in FH because the defect is genetic
Lifestyle changes are important adjuncts but rarely normalize LDL-C in FH; pharmacotherapy is almost always required (Correct answer)

Correct answer: Lifestyle changes are important adjuncts but rarely normalize LDL-C in FH; pharmacotherapy is almost always required

In FH, the defective LDL receptor limits the efficacy of lifestyle interventions; while helpful, lifestyle alone typically cannot achieve adequate LDL-C reduction without pharmacotherapy.

Question 117: Which cardiovascular risk factor is best addressed by assessing urine albumin-to-creatinine ratio (UACR) in a hypertensive diabetic patient?

Measuring triglyceride-rich lipoprotein clearance
Confirming statin eligibility
Detecting early chronic kidney disease as an ASCVD risk enhancer (Correct answer)
Identifying familial hypercholesterolemia

Correct answer: Detecting early chronic kidney disease as an ASCVD risk enhancer

Microalbuminuria (UACR 30–300 mg/g) signals early CKD, which is an independent ASCVD risk enhancer beyond traditional risk factors.

Question 118: The REDUCE-IT trial demonstrated that icosapentaenoic acid (EPA, 4g/day) reduced cardiovascular events by approximately what percentage in statin-treated patients with elevated triglycerides?

55%
25% (Correct answer)
10%
40%

Correct answer: 25%

REDUCE-IT showed icosapentaenoic acid (Vascepa) reduced major adverse cardiovascular events by approximately 25% relative to placebo in high-risk statin-treated patients.

Question 119: In the exogenous lipid pathway, chylomicrons are assembled in which cells?

Hepatocytes
Intestinal enterocytes (Correct answer)
Vascular endothelial cells
Adipocytes

Correct answer: Intestinal enterocytes

Chylomicrons are synthesized in intestinal enterocytes from dietary lipids and secreted into lymphatic lacteals before entering the circulation via the thoracic duct.

Question 120: Which dietary intervention has the strongest evidence for raising HDL-C levels?

Eliminating dietary cholesterol
Reducing saturated fat intake
Regular moderate-to-vigorous aerobic exercise (Correct answer)
Increasing dietary fiber

Correct answer: Regular moderate-to-vigorous aerobic exercise

Regular aerobic exercise is the most evidence-based lifestyle intervention for raising HDL-C, with increases of 3-9% typically observed.

Question 121: When comparing equivalent LDL-C-lowering doses, rosuvastatin achieves greater LDL-C reduction per milligram compared to atorvastatin. What approximate LDL-C reduction does rosuvastatin 10 mg achieve?

Approximately 37–45% reduction (moderate-intensity) (Correct answer)
Approximately 25–30% reduction (low-intensity)
Approximately 50–55% reduction (high-intensity)
Approximately 60–65% reduction (ultra-high intensity)

Correct answer: Approximately 37–45% reduction (moderate-intensity)

Rosuvastatin 10 mg achieves approximately 37–45% LDL-C reduction, classifying it as moderate-intensity therapy; only rosuvastatin 20–40 mg reaches high-intensity thresholds.

Question 122: What is a key principle of lifestyle modification & nutrition counseling in Clinical Lipid Specialist Certification practice?

Applying structured methodologies based on evidence and best practices (Correct answer)
Avoiding all standardized approaches
Relying solely on personal experience
Minimizing documentation requirements

Correct answer: Applying structured methodologies based on evidence and best practices

Lifestyle Modification & Nutrition Counseling in Clinical Lipid Specialist Certification practice requires applying structured, evidence-based methodologies while adapting to specific professional contexts.

Question 123: What is the recommended fasting period before lipid testing?

6–8 hours
No fasting needed
2–3 hours
9–12 hours (Correct answer)

Correct answer: 9–12 hours

A fasting period of 9-12 hours is typically recommended before a lipid panel to ensure accurate measurement of triglycerides and LDL cholesterol. Eating before the test can significantly elevate triglyceride levels, leading to inaccurate results. Only water is permitted during this fasting period.

Question 124: Which apolipoproteins are associated with HDL particles?

ApoE and ApoB-48
ApoB-100 and ApoC-III
ApoC-II and ApoB-100
ApoA-I and ApoA-II (Correct answer)

Correct answer: ApoA-I and ApoA-II

HDL particles are primarily characterized by ApoA-I and ApoA-II, which activate LCAT and facilitate cholesterol efflux from macrophages.

Question 125: In an FH patient who is pregnant, which lipid-lowering therapy is considered safest to continue?

Bile acid sequestrants (resins) (Correct answer)
Ezetimibe
High-intensity statin
PCSK9 inhibitor monoclonal antibody

Correct answer: Bile acid sequestrants (resins)

Bile acid sequestrants are not systemically absorbed and are the preferred option during pregnancy; statins, ezetimibe, and PCSK9 inhibitors are contraindicated or data are insufficient.

Question 126: Lipoprotein lipase (LPL) deficiency most commonly presents with which triglyceride phenotype?

Type III with IDL accumulation
Type I hyperlipoproteinemia with massive chylomicronemia (Correct answer)
Type IIa with isolated LDL elevation
Type IV with mild VLDL elevation

Correct answer: Type I hyperlipoproteinemia with massive chylomicronemia

LPL deficiency causes type I hyperlipoproteinemia, characterized by massive chylomicronemia and triglycerides often exceeding 1,000 mg/dL.

Question 127: In patients with chronic kidney disease (CKD) stages 3–5 not on dialysis, which lipid-lowering therapy is most supported by evidence?

Niacin to raise HDL-C
Statin or statin/ezetimibe combination based on SHARP trial evidence (Correct answer)
Fibrates as first-line therapy
PCSK9 inhibitors as first-line therapy

Correct answer: Statin or statin/ezetimibe combination based on SHARP trial evidence

The SHARP trial demonstrated that simvastatin/ezetimibe significantly reduced major atherosclerotic events in CKD patients not on dialysis.

Question 128: In the Reynolds Risk Score, which additional biomarker is incorporated compared to the Framingham Risk Score?

Apolipoprotein B and fibrinogen
Lipoprotein(a) and homocysteine
Ankle-brachial index and microalbuminuria
High-sensitivity CRP (hsCRP) and family history of premature MI (Correct answer)

Correct answer: High-sensitivity CRP (hsCRP) and family history of premature MI

The Reynolds Risk Score adds hsCRP and parental history of premature MI to traditional Framingham variables for improved risk discrimination.

Question 129: The DASH diet was originally designed to lower blood pressure, but it also improves lipid profiles. Which component most directly contributes to LDL reduction?

Emphasis on fruits, vegetables, whole grains, and low-fat dairy with limited saturated fat (Correct answer)
Restriction of all fats including polyunsaturated fats
High sodium restriction below 1,000 mg/day
High protein content from lean animal sources

Correct answer: Emphasis on fruits, vegetables, whole grains, and low-fat dairy with limited saturated fat

The DASH diet's emphasis on fiber-rich foods and replacement of saturated fat with unsaturated fat directly reduces LDL-C while also improving blood pressure.

Question 130: Which receptor mediates hepatic uptake of LDL particles through endocytosis?

CD36
PCSK9
LDL receptor (LDLR) (Correct answer)
SR-BI

Correct answer: LDL receptor (LDLR)

The LDL receptor (LDLR) recognizes ApoB-100 on LDL and mediates its uptake into hepatocytes via clathrin-coated pit endocytosis, where the receptor is recycled.

Question 131: What are chylomicrons?

Calcium regulators
Hormone molecules
Digestive enzymes
Lipid-transport particles (Correct answer)

Correct answer: Lipid-transport particles

Chylomicrons are large lipid-transport particles formed in the intestines after a meal. Their primary function is to transport dietary triglycerides and cholesterol from the digestive tract into the bloodstream. They deliver these fats to various tissues for energy or storage, playing a vital role in the absorption of dietary lipids.

Question 132: In familial hypercholesterolemia (FH), what is the most common molecular defect?

Loss-of-function mutation in the LDL receptor gene (Correct answer)
ApoE2 homozygosity
Deficiency of ApoC-II
Gain-of-function mutation in PCSK9

Correct answer: Loss-of-function mutation in the LDL receptor gene

The most common cause of FH is loss-of-function mutations in the LDLR gene, impairing LDL clearance and resulting in markedly elevated LDL-C from birth.

Question 133: Tendon xanthomas in FH patients are most commonly found at which anatomical site?

Rotator cuff tendons
Extensor tendons of the hands
Achilles tendon (Correct answer)
Patellar tendon

Correct answer: Achilles tendon

Achilles tendon xanthomas are the classic and most common tendinous xanthoma location in FH, detectable by ultrasound even when not palpable.

Question 134: Which omega-3 fatty acid has the strongest evidence for reducing cardiovascular events at prescription doses?

Alpha-linolenic acid (ALA) from flaxseed
Linoleic acid from vegetable oils
Docosahexaenoic acid (DHA) from algae supplements
Eicosapentaenoic acid (EPA) as icosapentaenoic acid ethyl ester (Correct answer)

Correct answer: Eicosapentaenoic acid (EPA) as icosapentaenoic acid ethyl ester

High-dose icosapentaenoic acid (EPA ethyl ester, 4g/day) demonstrated significant CV event reduction in the REDUCE-IT trial, distinct from ALA or DHA alone.

Question 135: What is the significance of measuring Lp(a) in children with familial hypercholesterolemia?

It differentiates homozygous from heterozygous FH
It guides dietary recommendations
It identifies those at higher cardiovascular risk requiring more aggressive therapy (Correct answer)
It determines statin dose titration

Correct answer: It identifies those at higher cardiovascular risk requiring more aggressive therapy

Elevated Lp(a) in children with FH confers additional atherosclerotic cardiovascular risk beyond LDL-C and should guide therapy intensity.

Question 136: A 52-year-old patient with metabolic syndrome is counseled on weight loss. Which statement about weight loss and lipids is most accurate?

Only weight loss greater than 20% improves lipid parameters
Weight loss primarily lowers LDL-C and has minimal effect on triglycerides
A 5-10% weight loss can significantly improve triglycerides and HDL (Correct answer)
Weight loss has no effect on HDL-C levels

Correct answer: A 5-10% weight loss can significantly improve triglycerides and HDL

Even modest weight loss of 5-10% of body weight produces clinically meaningful improvements in triglycerides, HDL-C, and non-HDL-C in patients with metabolic syndrome.

Question 137: Which condition is a major contributor to cardiovascular risk?

Asthma
Osteoarthritis
Diabetes mellitus (Correct answer)
Glaucoma

Correct answer: Diabetes mellitus

Diabetes mellitus is a major independent risk factor for cardiovascular disease. High blood glucose levels over time damage blood vessels and nerves, accelerating atherosclerosis and increasing the risk of heart attack, stroke, and peripheral artery disease. Effective management of diabetes is therefore critical for preventing cardiovascular complications.

Question 138: A non-fasting lipid panel is acceptable for initial cardiovascular risk screening primarily because which value is least affected by a recent meal?

HDL-C (Correct answer)
LDL-C by Friedewald equation
Triglycerides
VLDL-C

Correct answer: HDL-C

HDL-C remains relatively stable after meals and is the least postprandially affected major lipid fraction, making non-fasting panels useful for initial screening.

Question 139: Inclisiran differs from monoclonal antibody PCSK9 inhibitors in that it:

Is given as a daily oral tablet
Uses siRNA to suppress hepatic PCSK9 synthesis, allowing twice-yearly dosing (Correct answer)
Blocks LDL receptor recycling instead of PCSK9 binding
Only reduces Lp(a) without affecting LDL-C

Correct answer: Uses siRNA to suppress hepatic PCSK9 synthesis, allowing twice-yearly dosing

Inclisiran is an siRNA that silences PCSK9 mRNA in hepatocytes, reducing PCSK9 production and enabling dosing only twice per year after initiation.

Question 140: Which PCSK9 inhibitor was the first FDA-approved monoclonal antibody for reducing LDL-C in heterozygous FH?

Lomitapide
Bempedoic acid
Inclisiran
Alirocumab (Correct answer)

Correct answer: Alirocumab

Alirocumab (Praluent) was the first PCSK9 inhibitor approved by the FDA in 2015 for heterozygous FH management.

Question 141: A patient with severe hypertriglyceridemia (TG >1000 mg/dL) is at highest immediate risk for which complication?

Peripheral neuropathy
Xanthoma formation
Acute pancreatitis (Correct answer)
Atherosclerotic cardiovascular disease

Correct answer: Acute pancreatitis

Severely elevated triglycerides (>1000 mg/dL) pose the greatest immediate risk of acute pancreatitis, which can be life-threatening.

Question 142: When interpreting a lipid panel in a pregnant woman at 28 weeks gestation, what physiologic change is expected?

LDL-C and TG increase due to estrogen-mediated changes in lipoprotein metabolism (Correct answer)
HDL-C decreases markedly with no change in LDL-C or TG
All lipid fractions remain unchanged throughout pregnancy
LDL-C and TG decrease due to increased hepatic uptake

Correct answer: LDL-C and TG increase due to estrogen-mediated changes in lipoprotein metabolism

Pregnancy is associated with physiologic hyperlipidemia: LDL-C increases ~50%, TG may double or triple (especially in the third trimester), and HDL-C initially rises then plateaus due to estrogen and progesterone effects.

Question 143: Which lipoprotein is measured directly in the NMR-based advanced lipid panel that is NOT routinely captured in a standard fasting panel?

HDL3 subfraction
VLDL particle number
Chylomicron remnants
LDL particle number (LDL-P) (Correct answer)

Correct answer: LDL particle number (LDL-P)

NMR spectroscopy directly quantifies LDL particle number (LDL-P), which can diverge from LDL-C and may better predict cardiovascular risk in certain patients.

Question 144: Lp(a) is formed when LDL binds covalently to which protein?

Apolipoprotein(a) (Correct answer)
Fibrinogen
ApoC-III
ApoE

Correct answer: Apolipoprotein(a)

Lp(a) is formed by a disulfide bond between ApoB-100 on LDL and apolipoprotein(a), which structurally resembles plasminogen and may promote thrombosis and atherosclerosis.

Question 145: In reverse cholesterol transport, which lipoprotein particle delivers cholesterol to the liver for excretion?

VLDL
HDL (Correct answer)
IDL
Chylomicrons

Correct answer: HDL

HDL mediates reverse cholesterol transport by accepting free cholesterol from peripheral tissues and delivering it to the liver via SR-BI receptors or by transferring cholesterol esters to apoB-containing lipoproteins.

Question 146: Which cardiovascular risk assessment tool is most appropriate for FH patients given their lifelong elevated LDL-C exposure?

Pooled Cohort Equations (10-year)
Lifetime cardiovascular risk assessment adjusted for LDL burden years (Correct answer)
Framingham Risk Score (10-year)
SCORE2 European model

Correct answer: Lifetime cardiovascular risk assessment adjusted for LDL burden years

Standard 10-year risk calculators underestimate risk in FH because they do not account for decades of cumulative LDL-C exposure; lifetime risk models or FH-specific tools are more appropriate.

Question 147: What is the relationship between novel lipid-lowering therapies and overall Clinical Lipid Specialist Certification professional competency?

They are completely unrelated areas
It is an essential component that strengthens the overall competency framework (Correct answer)
It is a minor supplementary skill
It only applies to senior practitioners

Correct answer: It is an essential component that strengthens the overall competency framework

Novel Lipid-Lowering Therapies is an essential component of the CLS competency framework, strengthening overall professional capability and credibility.

Question 148: Which type of dietary fiber has the greatest evidence for LDL cholesterol reduction?

Insoluble fiber found in wheat bran
Soluble viscous fiber found in oats and psyllium (Correct answer)
Cellulose from leafy green vegetables
Resistant starch from cooked and cooled potatoes

Correct answer: Soluble viscous fiber found in oats and psyllium

Soluble viscous fibers (beta-glucan from oats, psyllium) bind bile acids in the gut, increasing fecal excretion and reducing hepatic LDL-C, with a well-established evidence base.

Question 149: A CAC score of zero in a low-to-intermediate risk patient most appropriately supports which management decision?

Immediate high-intensity statin initiation
Referral for coronary angiography
Withholding statin therapy and reassessing in 5–10 years (Correct answer)
Adding PCSK9 inhibitor therapy

Correct answer: Withholding statin therapy and reassessing in 5–10 years

A CAC of zero confers a very low near-term event rate, supporting deferral of statin therapy with reassessment in 5–10 years.

Question 150: In the context of metabolic syndrome, which pattern of lipoprotein abnormality is most characteristic?

Elevated chylomicrons with normal VLDL
Isolated elevation of LDL-C with normal triglycerides
Elevated Lp(a) with normal triglycerides and HDL-C
Low HDL-C, elevated triglycerides, and small dense LDL particles (Correct answer)

Correct answer: Low HDL-C, elevated triglycerides, and small dense LDL particles

Metabolic syndrome is associated with an atherogenic dyslipidemia triad: elevated triglycerides, low HDL-C, and increased small dense LDL particles, driven by insulin resistance and excess hepatic VLDL production.

Question 151: What is a key principle of familial hypercholesterolemia management in Clinical Lipid Specialist Certification practice?

Relying solely on personal experience
Avoiding all standardized approaches
Minimizing documentation requirements
Applying structured methodologies based on evidence and best practices (Correct answer)

Correct answer: Applying structured methodologies based on evidence and best practices

Familial Hypercholesterolemia Management in Clinical Lipid Specialist Certification practice requires applying structured, evidence-based methodologies while adapting to specific professional contexts.

Question 152: CETP (cholesteryl ester transfer protein) primarily facilitates which lipid exchange?

Triglycerides from HDL to LDL/VLDL for cholesterol esters (Correct answer)
Cholesterol from liver to peripheral tissues
Phospholipids from LDL to HDL
Free fatty acids from adipose to liver

Correct answer: Triglycerides from HDL to LDL/VLDL for cholesterol esters

CETP transfers cholesteryl esters from HDL to VLDL and LDL in exchange for triglycerides, lowering HDL-C and raising triglycerides in VLDL.

Clinical Lipid Specialist (CLS) Certification Exam

The CLS certification validates advanced knowledge and expertise in lipidology, including the diagnosis, management, and prevention of dyslipidemia and related cardiovascular diseases.

150

Questions

180 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds

These practice questions were written with AI tools. They are not real exam questions. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy

Sources & references

Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy

lipidboard.org — Renewal, score validity, test delivery, exam format, time limit, fees, registration deadline, test dates · verified Oct 2026